Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Adma Biologics Inc’s stock clocked out at $14.03, down -8.72% from its previous closing price of $15.37. In other words, the price has decreased by -$8.72 from its previous closing price. On the day, 9.49 million shares were traded. ADMA stock price reached its highest trading level at $15.24 during the session, while it also had its lowest trading level at $13.83.
Ratios:
To gain a deeper understanding of ADMA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 54.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 82.20. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 24 ’25 when Grossman Adam S sold 21,000 shares for $16.00 per share. The transaction valued at 336,000 led to the insider holds 2,019,850 shares of the business.
Grossman Adam S. bought 63,000 shares of ADMA for $960,750 on Oct 24 ’25. On Sep 15 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $16.13 each. As a result, the insider received 338,730 and left with 2,025,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 3339108608 and an Enterprise Value of 3661294080. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.48, and their Forward P/E ratio for the next fiscal year is 15.36. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.42. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.85 while its Price-to-Book (P/B) ratio in mrq is 7.75. Its current Enterprise Value per Revenue stands at 7.721 whereas that against EBITDA is 22.386.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.46, which has changed by -0.32051283 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -9.07%, while the 200-Day Moving Average is calculated to be -21.51%.
Shares Statistics:
It appears that ADMA traded 3.47M shares on average per day over the past three months and 3662650 shares per day over the past ten days. A total of 238.33M shares are outstanding, with a floating share count of 230.46M. Insiders hold about 3.42% of the company’s shares, while institutions hold 86.24% stake in the company. Shares short for ADMA as of 1760486400 were 17560695 with a Short Ratio of 5.05, compared to 1757894400 on 15740996. Therefore, it implies a Short% of Shares Outstanding of 17560695 and a Short% of Float of 9.04.
Earnings Estimates
A comprehensive evaluation of Adma Biologics Inc (ADMA) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.21, with high estimates of $0.21 and low estimates of $0.21.
Analysts are recommending an EPS of between $0.59 and $0.59 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $0.95, with 1 analysts recommending between $0.95 and $0.95.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $140.05M. It ranges from a high estimate of $140.3M to a low estimate of $139.8M. As of. The current estimate, Adma Biologics Inc’s year-ago sales were $117.55MFor the next quarter, 2 analysts are estimating revenue of $145.1M. There is a high estimate of $149M for the next quarter, whereas the lowest estimate is $142M.
A total of 2 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $511.3M, while the lowest revenue estimate was $510.9M, resulting in an average revenue estimate of $511.1M. In the same quarter a year ago, actual revenue was $426.45MBased on 3 analysts’ estimates, the company’s revenue will be $634.73M in the next fiscal year. The high estimate is $642M and the low estimate is $631M.
